AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16391891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (1 mg/kg)
Number of subjects: 27
Study 16391891 — intervention group
Group type: COMPARATOR
Intervention: Synthetic human calcitonin (1.5 mg)
Number of subjects: 27
Study 15220685 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily, amoxicillin 1 g, clarithromycin 500 mg (EAC1 group, n = 52)
Number of subjects: 156
Study 15220685 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg (OAC group, n = 52)
Number of subjects: 156
Study 15220685 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg (EAC2 group, n = 52)
Number of subjects: 156
Study 11055773 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Betula 30c
Number of subjects: 73
Study 11055773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 9120173 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 358
Study 9120173 — intervention group
Group type: COMPARATOR
Intervention: Tissue-type plasminogen activator (t-PA)
Number of subjects: 358
Study 8384011 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimonate (10 mg of antimony/kg intramuscularly, twice a day for 20 days)
Number of subjects: 92
Study 8384011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine (2 mg/kg every other day intramuscularly, for a total of seven injections)
Number of subjects: 92
Study 8384011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine (2 mg/kg every other day for a total of only four injections)
Number of subjects: 92
Study 8384011 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (200 mg orally, twice a day for 28 days)
Number of subjects: 92
Study 8384011 — intervention group
Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 92
Study 3774823 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (1.84% THC)
Number of subjects: 9
Study 3774823 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (2-3 cigarettes during social access period)
Number of subjects: 9
Study 3774823 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 9
Study 29505880 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (PCV) for 14 days
Number of subjects: 188
Study 29505880 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin for 14 days
Number of subjects: 188
Study 29505880 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline for 14 days
Number of subjects: 188
Study 29505880 — intervention group
Group type: COMPARATOR
Intervention: All treatments (PCV, amoxicillin, doxycycline)
Number of subjects: 188
Study 29505880 — intervention group
Group type: COMPARATOR
Intervention: Follow-up for 1 year
Number of subjects: 188
Study 26455342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 129
Study 26455342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine >60 minutes after initial PVI
Number of subjects: 129
Study 26455342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine <60 minutes after initial PVI
Number of subjects: 129
Study 26455342 — intervention group
Group type: COMPARATOR
Intervention: No adenosine (Control)
Number of subjects: 129
Study 24530993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexyl 5‐aminolevulinate hydrochloride (HAL) at a dose of 6.25mg/ml
Number of subjects: 12
Study 24530993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexyl 5‐aminolevulinate hydrochloride (HAL) at a dose of 50mg/ml
Number of subjects: 12
Study 24530993 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 22932169 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FORM (160/4.5 µg/inhalation) + as-needed BUD/FORM (640/18 µg/d)
Number of subjects: 222
Study 22932169 — intervention group
Group type: COMPARATOR
Intervention: SALM/FP (100/1000 µg/d) + as-needed terbutaline (0.4 mg/inhalation)
Number of subjects: 222
Study 19736370 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactional group discussions
Number of subjects: 72
Study 19736370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 17852284 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday Memory Questionnaire-revised (EMQ-R)
Number of subjects: 0
Study 17852284 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday Memory Questionnaire (EMQ-28)
Number of subjects: 0
Study 17852284 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-clinical)
Number of subjects: 0
Study 15861510 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based teaching program
Number of subjects: 225
Study 15861510 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching program
Number of subjects: 225
Study 15861510 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based teaching program (1999 and 2000)
Number of subjects: 225
Study 12025234 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of receptor tyrosine kinases (RTK) and Ras
Number of subjects: 0
Study 12025234 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural and synthetic compounds, monoclonal antibodies, and antisense oligonucleotides as inhibitors of signal transduction
Number of subjects: 0
Study 11773987 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil SR/trandolapril 180/2 mg (VT)
Number of subjects: 93
Study 11773987 — intervention group
Group type: COMPARATOR
Intervention: enalapril/hydroclorothiazide 20/12.5 mg (EH)
Number of subjects: 93
Study 9022869 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-and-skills-building workshop for chemical dependency staff on treatment of nicotine dependence
Number of subjects: 6
Study 9022869 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no staff training provided)
Number of subjects: 6
Study 8517568 — intervention group
Group type: EXPERIMENTAL
Intervention: No needle change (venipuncture)
Number of subjects: 940
Study 8517568 — intervention group
Group type: COMPARATOR
Intervention: Needle change (venipuncture)
Number of subjects: 940
Study 8517568 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly inserted IV cannula
Number of subjects: 940
Study 8517568 — intervention group
Group type: COMPARATOR
Intervention: Standard method (venipuncture with needle change)
Number of subjects: 940
Study 8517568 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cannula
Number of subjects: 940
Study 3782428 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC; 150 mg) for 5 days
Number of subjects: 7
Study 3782428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30213463 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 65
Study 30213463 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 65
Study 30213463 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + CPAP
Number of subjects: 65
Study 30213463 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and CPAP
Number of subjects: 65
Study 30213463 — intervention group
Group type: COMPARATOR
Intervention: Exercise groups
Number of subjects: 65
Study 27277213 — intervention group
Group type: EXPERIMENTAL
Intervention: ART with TB treatment
Number of subjects: 76
Study 27277213 — intervention group
Group type: COMPARATOR
Intervention: TB treatment only
Number of subjects: 76
Study 27277213 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 76
Study 24934094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuvola® aligner
Number of subjects: 2
Study 24934094 — intervention group
Group type: COMPARATOR
Intervention: Fantasmino® system
Number of subjects: 2
Study 22923289 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1,000 IU/day)
Number of subjects: 103
Study 22923289 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1,000 IU/day) in FF subjects (n = 47)
Number of subjects: 103
Study 22923289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 20012447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture delivery
Number of subjects: 52
Study 20012447 — intervention group
Group type: COMPARATOR
Intervention: Control (rest day)
Number of subjects: 52
Study 18711188 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-3512676 (0.2 mg/kg subcutaneously on days 8 and 15 of each 3-week cycle)
Number of subjects: 111
Study 18711188 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 111
Study 16162141 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococcus faecalis isolates
Number of subjects: 35
Study 12558709 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical collagen daily
Number of subjects: 65
Study 12558709 — intervention group
Group type: COMPARATOR
Intervention: Topical hydrocolloid twice weekly
Number of subjects: 65
Study 9869576 — intervention group
Group type: EXPERIMENTAL
Intervention: Double combination of zidovudine (ZDV) plus didanosine (ddI)
Number of subjects: 175
Study 9869576 — intervention group
Group type: COMPARATOR
Intervention: Triple combination of nevirapine (NVP) plus ZDV plus ddI
Number of subjects: 175
Study 9869576 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination of NVP plus ZDV plus ddI
Number of subjects: 175
Study 8779500 — intervention group
Group type: EXPERIMENTAL
Intervention: Biogel Super‐Sensitive gloves
Number of subjects: 0
Study 8779500 — intervention group
Group type: COMPARATOR
Intervention: Standard Biogel gloves
Number of subjects: 0
Study 1669595 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine once daily
Number of subjects: 40
Study 1669595 — intervention group
Group type: COMPARATOR
Intervention: 10 mg loratadine once daily
Number of subjects: 40
Study 30860069 — intervention group
Group type: EXPERIMENTAL
Intervention: Four courses of adjuvant S-1
Number of subjects: 0
Study 30860069 — intervention group
Group type: COMPARATOR
Intervention: Eight courses of adjuvant S-1
Number of subjects: 0
Study 28752894 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) and weight loss
Number of subjects: 165
Study 28752894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB) and weight loss
Number of subjects: 165
Study 26375541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl ITS (40 mcg/activation)
Number of subjects: 170
Study 26375541 — intervention group
Group type: COMPARATOR
Intervention: IV PCA morphine (1 mg/dose)
Number of subjects: 170
Study 23418751 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinfold thickness measurement (SFTM)
Number of subjects: 49
Study 21537587 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal Sealing (n=48)
Number of subjects: 66
Study 21537587 — intervention group
Group type: EXPERIMENTAL
Intervention: Refurbishment (n=73)
Number of subjects: 66
Study 21537587 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair (n=27)
Number of subjects: 66
Study 21537587 — intervention group
Group type: COMPARATOR
Intervention: Replacement (n=42)
Number of subjects: 66
Study 21537587 — intervention group
Group type: COMPARATOR
Intervention: Untreated (n=81)
Number of subjects: 66
Study 19138701 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-work induced transient myopia (NITM) in progressing myopes (PMs)
Number of subjects: 3
Study 19138701 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state accommodative stimulus response curve (ASRC)
Number of subjects: 3
Study 19138701 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-work induced transient myopia (NITM)
Number of subjects: 3
Study 18074759 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 36
Study 18074759 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 36
Study 15177522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/d for 6 months
Number of subjects: 52
Study 15177522 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 500 mg/d for 6 months
Number of subjects: 52
Study 11589258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/APAP (37.5 mg/325 mg)
Number of subjects: 462
Study 11589258 — intervention group
Group type: COMPARATOR
Intervention: Codeine/APAP (30 mg/300 mg)
Number of subjects: 462
Study 11477815 — intervention group
Group type: EXPERIMENTAL
Intervention: Xianzhen Tablet (XZT) treated group, 30 patients, 8 weeks treatment
Number of subjects: 60
Study 11477815 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study 8608658 — intervention group
Group type: EXPERIMENTAL
Intervention: PAN DX membrane dialyzer
Number of subjects: 12
Study 8608658 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone membrane dialyzer
Number of subjects: 12
Study 8608658 — intervention group
Group type: COMPARATOR
Intervention: Concurrent ACE inhibitor
Number of subjects: 12
Study 8608658 — intervention group
Group type: COMPARATOR
Intervention: No ACE inhibitor
Number of subjects: 12
Study 2756523 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of propafenone on days 1 and 4, 1200 mg/day on days 2 and 3
Number of subjects: 10
Study 2756523 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of propafenone on days 1 and 4, 1200 mg/day on days 2 and 3
Number of subjects: 10
Study 2756523 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 10
Study 68382 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-current bone-growth stimulator
Number of subjects: 0
Study 68382 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31102525 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) in blood pressure (BP) measured as standard deviation (SD) of systolic blood pressure (SBP)
Number of subjects: 10051
Study 31102525 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient of variation (CV) of SBP
Number of subjects: 10051
Study 31131517 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Training (AT)
Number of subjects: 48
Study 31131517 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 48
Study 31131517 — intervention group
Group type: COMPARATOR
Intervention: Combined Training (CT)
Number of subjects: 48
Study 28240587 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly
Number of subjects: 213
Study 28240587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 28240587 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme scores (enthesitis and/or BASDAI)
Number of subjects: 213
Study 25979190 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied during the bone consolidation period following mandibular distraction osteogenesis.
Number of subjects: 10
Study 25979190 — intervention group
Group type: COMPARATOR
Intervention: Mandibular distraction osteogenesis without LLLT (Control group).
Number of subjects: 10
Study 24287217 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) cycling four times a week for two weeks
Number of subjects: 14
Study 24287217 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation for two weeks
Number of subjects: 14
Study 21527222 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-plasty during two-stage hypospadias repair (Group I)
Number of subjects: 43
Study 21527222 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary Z-plasty (Group II)
Number of subjects: 43
Study 21527222 — intervention group
Group type: COMPARATOR
Intervention: Midline vertical closure (Group III - Control)
Number of subjects: 43
Study 18272020 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg morphine sulphate (p.o.)
Number of subjects: 18
Study 18272020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16951513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice care
Number of subjects: 76
Study 16951513 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 76
Study 15055563 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous nasal spray (TAA AQ), 220 microg everyday for 21 days
Number of subjects: 39
Study 15055563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP AQ), 200 microg everyday for 21 days
Number of subjects: 39
Study 11093991 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 81
Study 11093991 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 81
Study 9460590 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol therapy for 6 months
Number of subjects: 0
Study 8463375 — intervention group
Group type: EXPERIMENTAL
Intervention: Frightening story
Number of subjects: 132
Study 8463375 — intervention group
Group type: EXPERIMENTAL
Intervention: Frightening-happy end story
Number of subjects: 132
Study 8463375 — intervention group
Group type: COMPARATOR
Intervention: Pause story
Number of subjects: 132
Study 8463375 — intervention group
Group type: COMPARATOR
Intervention: Neutral story
Number of subjects: 132
Study 3456621 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg PGE2/day/patient (5 mg every 4 hours, 4 times a day)
Number of subjects: 10
Study 3456621 — intervention group
Group type: COMPARATOR
Intervention: 20 mg lactose/day/patient (placebo)
Number of subjects: 10
Study 3456621 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate
Number of subjects: 10
Study 31914436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with or without ipilimumab
Number of subjects: 2
Study 31914436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 2
Study 29448361 — intervention group
Group type: EXPERIMENTAL
Intervention: Real networks
Number of subjects: 0
Study 29448361 — intervention group
Group type: COMPARATOR
Intervention: Degree-preserving randomizations
Number of subjects: 0
Study 29448361 — intervention group
Group type: EXPERIMENTAL
Intervention: Certain real networks
Number of subjects: 0
Study 29448361 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrelated random networks
Number of subjects: 0
Study 26859101 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole plus fulvestrant
Number of subjects: 694
Study 26859101 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole alone
Number of subjects: 694
Study 24763475 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX
Number of subjects: 35
Study 24763475 — intervention group
Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 35
Study 23442835 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg, Esomeprazole 40 mg
Number of subjects: 11831
Study 23442835 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg, Lansoprazole 30 mg
Number of subjects: 11831
Study 23442835 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole vs. Placebo
Number of subjects: 11831
Study 23442835 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 11831
Study 19881393 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 30 mg/kg
Number of subjects: 120
Study 19881393 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 20 mg/kg
Number of subjects: 120
Study 19881393 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 50 mg/kg for 5 days
Number of subjects: 120
Study 19881393 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (control)
Number of subjects: 120
Study 18948636 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1.8 g daily for 3 months
Number of subjects: 0
Study 18948636 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-treated groups
Number of subjects: 0
Study 17304477 — intervention group
Group type: EXPERIMENTAL
Intervention: Teletherapy combined with radioisotope therapy
Number of subjects: 84
Study 17304477 — intervention group
Group type: COMPARATOR
Intervention: Teletherapy
Number of subjects: 84
Study 17304477 — intervention group
Group type: COMPARATOR
Intervention: Radioisotope therapy
Number of subjects: 84
Study 17304477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (radiotherapy and radioisotopes)
Number of subjects: 84
Study 12711881 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous low-energy intracardiac biphasic direct-current (DC) cardioversion (ICV) using a single-lead balloon-tipped catheter
Number of subjects: 54
Study 12711881 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-energy transthoracic monophasic DC cardioversion (TCV)
Number of subjects: 54
Study 12711881 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after ICV
Number of subjects: 54
Study 11908358 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Maximum Strength Toothpaste (5.0% potassium nitrate, 0.454% stannous fluoride)
Number of subjects: 120
Study 11908358 — intervention group
Group type: COMPARATOR
Intervention: Sensodyne Fresh Mint Toothpaste (5.0% potassium nitrate, 0.243% sodium fluoride)
Number of subjects: 120
Study 11908358 — intervention group
Group type: COMPARATOR
Intervention: Colgate Winterfresh Gel (0.243% sodium fluoride)
Number of subjects: 120
Study 8731383 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (100 micrograms/kg)
Number of subjects: 73
Study 8731383 — intervention group
Group type: COMPARATOR
Intervention: Cu/Zn‐SOD activity
Number of subjects: 73
Study 8731383 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E, vitamin C, and beta‐carotene
Number of subjects: 73
Study 8731383 — intervention group
Group type: COMPARATOR
Intervention: Catalase activity
Number of subjects: 73
Study 1578940 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (Allo-BMT)
Number of subjects: 155
Study 1578940 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplant (Auto-BMT)
Number of subjects: 155
Study 1578940 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 155
Study 1578940 — intervention group
Group type: EXPERIMENTAL
Intervention: Not randomized patients (intention to treat analysis)
Number of subjects: 155
Study 3862020 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0